HSD11B2 encodes 11β-hydroxysteroid dehydrogenase type 2, an NAD-dependent enzyme that catalyzes the conversion of biologically active glucocorticoids (cortisol) to inactive metabolites (cortisone) 1. This enzyme protects mineralocorticoid receptors from glucocorticoid excess by serving as a high-affinity dehydrogenase that decreases active glucocorticoid concentrations 1. HSD11B2 also metabolizes androgens, converting 11β-hydroxytestosterone to 11-ketotestosterone, and processes cholesterol derivatives involved in immune cell migration 2. Mutations in HSD11B2 cause apparent mineralocorticoid excess (AME), a potentially fatal autosomal recessive disorder characterized by severe juvenile hypertension, growth failure, hypokalemia, and suppressed renin-aldosterone levels 34. AME results from cortisol acting as a potent mineralocorticoid due to deficient 11β-HSD2 activity 3. The enzyme's expression is regulated by epigenetic mechanisms including DNA methylation and microRNAs, with altered regulation contributing to salt-sensitive hypertension 5. Early diagnosis and treatment of AME through genetic testing can prevent end-organ damage, while enzyme activity correlates with salt sensitivity in essential hypertension 46.